Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (156) clinical trials

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab for Treatment of Hematologic Malignancies

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Phase

Fludarabine Cyclophosphamide and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

OBJECTIVES: - Determine the frequency, extent, and rate of donor (myeloid and lymphoid) engraftment in patients with serious hematologic malignancies treated with nonmyeloablative conditioning regimen comprising fludarabine, cyclophosphamide, and low-dose total-body irradiation followed by unrelated allogeneic umbilical cord blood transplantation and post-transplant immunosuppression comprising cyclosporine and mycophenolate mofetil. - Correlate ...

Phase N/A

Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

OBJECTIVES: Primary - Determine the test characteristics of galactomannan (GM) ELISA using serum and bronchoalveolar lavage fluid (BALF) collected from patients at high risk of invasive fungal infection. - Determine the test characteristics of aspergillus PCR using blood and BALF samples collected from these patients. - Evaluate the role of ...

Phase N/A

Submission of Stem Cell Transplant Data to CIBMTR and NMDP

Background: - In 2005, the United States Congress legislated that outcome data would be collected on all patients who have been recipients of a stem cell therapeutics product (including bone marrow, cord blood, or other such product) from a donor. The Health Services and Resources Administration (HRSA) awarded the contract ...

Phase N/A

Extracorporal Photopheresis Pilot Study

ECP will be given to the patients [UVAR®XTS TM Therakos system, Johnson & Johnson] according to the following schedule: Starting at day 21 after transplant, if hematologic recovery allowed it: 2 ECP per week the first 2 weeks, and 1 ECP per week during 1 month. Total = 8 ECP ...

Phase

A Phase 1 Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.

Phase

Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders

To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.

Phase N/A

Screening Individuals and Families at High Risk for Hematologic Cancers

OBJECTIVES: - Ascertain individuals at high risk for hematologic malignancy because of personal or family medical history. - Evaluate and define the clinical spectrum and natural history of disease in syndromes predisposing these individuals and families to hematologic cancer. - Evaluate the potential precursor states of malignancy in families at ...

Phase N/A

Allogeneic Hematopoietic Stem Cell Transplantation

Primary criterion - Hematological reconstitution and chimerism post-transplantation Secondary criteria - Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions - Analysis of variations in post-transplantation immunological function profiles - Median duration of response in therapy-responsive patients and median duration ...

Phase